Cellectis
↗Paris, France
Cellectis is a clinical-stage biotechnology company that pioneers gene-editing technologies to develop life-saving cell and gene therapies. The company utilizes its proprietary TALEN® gene-editing platform and PulseAgile electroporation system to create allogeneic, off-the-shelf CAR T-cell immunotherapies for oncology and other therapeutic indications.
Headquartered in Paris, France, with significant operations in New York and Raleigh, North Carolina, Cellectis controls the end-to-end value chain for its therapies, including in-house manufacturing capabilities. The company is focused on addressing high unmet medical needs by developing standardized, cost-effective, and readily available treatments for patients.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$70M-$80M
Founded:1999
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
STOCK
Exchange:NASDAQ
Ticker:CLLS
Market Cap:$0.43B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (lasme-cel)
Modalities:Cell therapy, Gene therapy
Active Trials:7
Trial Phases:Phase 1: 4 | Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AstraZeneca (Joint Research and Collaboration Agreement), Allogene Therapeutics/Servier (License for CD19 products)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, Kite Pharma
LEADERSHIP
Key Executives:
André Choulika - CEO & Co-Founder
Arthur Stril - Chief Business Officer & Interim CFO
Philippe Duchateau - Chief Scientific Officer
Scientific Founders:André Choulika, David Sourdive
Board Members:Jean-Pierre Garnier, André Choulika, David Sourdive
LINKS
Website:cellectis.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Cellectis and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cellectis. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.